biostudies-literatureUnknown14(9)Ferrer RPfizer Inc<h4>Introduction</h4>Treatments for serious infections caused by multidrug-resistant gram-negative bacteria, including metallo-β-lactamase-producing Enterobacterales (MBL-EB), are limited and aztreonam with avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor combination active against MBL-EB approved in Europe and approved for reimbursement by the Spanish National Health System (NHS). This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM-AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective.<h4>Methods</h4>A dynamic disease transmission model was develoInfectious diseases and therapy2071-2092https://www.ebi.ac.uk/biostudies/studies/S-EPMC12425856biostudies-literatureEstimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework.PMC12425856Nikolova SLuque SZormpas EMaroto-Diaz MDennis Jde Lossada Ade Ceano-Vivas MCGheorghe MBroughton EMoreno YFerrer RMartinez-Martinez LMoya-Alarcon CfalseEstimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework.<h4>Introduction</h4>Treatments for serious infections caused by multidrug-resistant gram-negative bacteria, including metallo-β-lactamase-producing Enterobacterales (MBL-EB), are limited and aztreonam with avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor combination active against MBL-EB approved in Europe and approved for reimbursement by the Spanish National Health System (NHS). This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM-AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective.<h4>Methods</h4>A dynamic disease transmission model was develo2025-01-01T00:00:00Z2025 Sep2026-06-03T02:50:34.426Z2026-04-23T03:11:42.332ZS-EPMC124258564071994710.1007/s40121-025-01202-6